[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489459":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":190,"collaborators":192,"id":196,"slug":197,"hasResults":198,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":10,"eligibilityCriteria":202,"healthyVolunteers":198,"sex":203,"minAge":10,"maxAge":10,"enrollmentInfo":204,"targetDuration":10,"studyType":207,"phases":10,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Enrolled Subjects",null,"Once enrolled subjects will provide Optional Archival Tissue, Optional Fresh tumor for a biopsy and blood collections at baseline, optional day 8 of cycle 1, day 1 of cycles 2-6 and at progression",[13],"Other: Plasma Collection",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Plasma Collection","Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes",[9],[20],{"name":21,"affiliation":5,"role":22},"Scott Schuetze","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","734-647-8921","scotschu@med.umich.edu",[29,50,64,77,93,106,118,131,145,160,176],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Sarcoma Oncology Research Center","RECRUITING","Santa Monica","California","90403","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-118.49138,34.01949,{"lat":41,"lon":40},[44,48],{"name":45,"role":25,"phone":46,"phoneExt":10,"email":47},"Allyssa Lingad","310-552-9999","alingad@sarcomaoncology.com",{"name":49,"role":22,"phone":10,"phoneExt":10,"email":10},"Sant P Chawla, MD",{"facility":51,"status":31,"city":52,"state":53,"zip":54,"country":35,"countryCode":36,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"University of Miami","Miami","Florida","33136",{"type":38,"coordinates":56},[57,58],-80.19366,25.77427,{"lat":58,"lon":57},[61,63],{"name":62,"role":25,"phone":10,"phoneExt":10,"email":10},"Gina D'Amato, MD",{"name":62,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":65,"status":31,"city":66,"state":67,"zip":68,"country":35,"countryCode":36,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Dana- Farber","Boston","Massachusetts","02215",{"type":38,"coordinates":70},[71,72],-71.05977,42.35843,{"lat":72,"lon":71},[75],{"name":76,"role":25,"phone":10,"phoneExt":10,"email":10},"David Shulman, MD",{"facility":78,"status":31,"city":79,"state":80,"zip":81,"country":35,"countryCode":36,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"University of Michigan Cancer Center","Ann Arbor","Michigan","48109",{"type":38,"coordinates":83},[84,85],-83.74088,42.27756,{"lat":85,"lon":84},[88,91],{"name":89,"role":25,"phone":90,"phoneExt":10,"email":10},"Scott Schuetze, M.D., PhD.","734-647-8925",{"name":92,"role":22,"phone":10,"phoneExt":10,"email":10},"Scott Schuetze, M.D., PhD",{"facility":94,"status":31,"city":95,"state":96,"zip":97,"country":35,"countryCode":36,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Mayo Clinic","Rochester","Minnesota","55901",{"type":38,"coordinates":99},[100,101],-92.4699,44.02163,{"lat":101,"lon":100},[104],{"name":105,"role":25,"phone":10,"phoneExt":10,"email":10},"Brittany Siontis, MD",{"facility":107,"status":31,"city":108,"state":108,"zip":109,"country":35,"countryCode":36,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":38,"coordinates":111},[112,113],-74.00597,40.71427,{"lat":113,"lon":112},[116],{"name":117,"role":25,"phone":10,"phoneExt":10,"email":10},"Sujana Movva, MD",{"facility":119,"status":31,"city":120,"state":121,"zip":122,"country":35,"countryCode":36,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Ohio State University","Columbus","Ohio","43210",{"type":38,"coordinates":124},[125,126],-82.99879,39.96118,{"lat":126,"lon":125},[129],{"name":130,"role":25,"phone":10,"phoneExt":10,"email":10},"Gabriel Tinoco, MD",{"facility":132,"status":31,"city":133,"state":134,"zip":135,"country":35,"countryCode":36,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":38,"coordinates":137},[138,139],-86.78444,36.16589,{"lat":139,"lon":138},[142],{"name":143,"role":25,"phone":144,"phoneExt":10,"email":10},"Elizabeth J Davis, MD","615-322-5000",{"facility":146,"status":31,"city":147,"state":148,"zip":149,"country":35,"countryCode":36,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"MD Anderson","Houston","Texas","77030",{"type":38,"coordinates":151},[152,153],-95.36327,29.76328,{"lat":153,"lon":152},[156],{"name":157,"role":25,"phone":158,"phoneExt":10,"email":159},"Elise Nassif Haddad, MD, PhD","281-460-0607","efnassif@mdanderson.org",{"facility":161,"status":31,"city":162,"state":163,"zip":164,"country":165,"countryCode":166,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"Chris O'Brien Lifehouse","Camperdown","New South Wales","2050","Australia","AU",{"type":38,"coordinates":168},[169,170],151.17642,-33.88965,{"lat":170,"lon":169},[173],{"name":174,"role":25,"phone":10,"phoneExt":10,"email":175},"Peter Grimison","Peter.grimison@lh.org.au",{"facility":177,"status":31,"city":178,"state":179,"zip":180,"country":165,"countryCode":166,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Peter MacCallum Cancer Centre","Melbourne","Victoria","3000",{"type":38,"coordinates":182},[183,184],144.96332,-37.814,{"lat":184,"lon":183},[187],{"name":188,"role":25,"phone":10,"phoneExt":10,"email":189},"Stephen Luen","stephen.luen@petermac.org",{"type":191,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[193],{"name":194,"class":195},"National Cancer Institute (NCI)","NIH","100489459","metastatic-leiomyosarcoma-biomarker-protocol-100489459",false,"NCT05653388","Metastatic Leiomyosarcoma Biomarker Protocol","Observational Study of Biomarkers of Disease-related Outcomes in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy","Inclusion Criteria:\n\n* Patients with unresectable or metastatic leiomyosarcoma (LMS). There is no age requirement\n* Receiving first-line chemotherapy with doxorubicin- based or gemcitabine\u002Fdocetaxel\n* Target lesions per RECIST 1.1\n* Optional archival tumor tissue including 1 H\\&E-stained slide and unstained tumor tissue \\[either tissue block containing tumor, or minimum of 4 unstained slides (preferably 8 unstained slides)-fresh frozen sample may also be used in lieu of FFPE sample\\] available for study research","ALL",{"count":205,"type":206},200,"ESTIMATED","OBSERVATIONAL","Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced\u002Fmetastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.",[210],"Leiomyosarcoma",[212,213,214],"ctDNA","Biomarker","radiomics","2026-06-23",{"date":217,"type":218},"2026-06-24","ACTUAL",{"date":220,"type":218},"2022-12-22",{"date":222,"type":206},"2026-12",{"name":5,"class":6},11]